Sangmi Lee
Clinical Development Head ABL Bio
Seminars
Wednesday 10th June 2026
Optimizing T-Cell Engaging Therapies from Preclinical Study to Human Clinical Trials: Conditional Activation of T-Cells in the Tumor Microenvironment by a Novel 4-1BB T-Cell Engaging BsAb (Grabody T)
9:45 am
- Outlining the Grabody T platform, a clinically validated 4-1BB bispecific antibody approach to overcoming liver toxicity
- Unveiling how the targeted activation of Grabody T exhibits TAA-dependent 4-1BB activation and strong in vivo efficacy
- Examining the promising clinical activity and favorable safety profile across the Grabody T pipeline (Givastomig, Ragistomig, and YH32367)
